ELTX

Elicio is a pre-revenue, clinical-stage immuno-oncology company whose entire value rests on one asset: ELI-002 7P in the Phase 2 AMPLIFY-7P trial for mKRAS pancreatic cancer. The 'revenue' that produces a 32x P/S is legacy noise — the last real top line was $28.3M in FY2021 (Angion-era), collapsing to $2.3M in FY2022 and effectively zero since. There is no commercial business here; the company states plainly it 'has never generated revenue from product sales and may never become profitable.' Valuing it on sales multiples is meaningless, and the headline ratios (operating margin -1,639%, ROE -2,419%) simply reflect a research shop burning cash with no offsetting income.

The balance sheet is the disqualifying problem. FY2025 closed with just $18.6M cash against a $37.0M annual operating cash burn — roughly six months of runway from the December 31 measurement date, meaning by today (June 2026) the company is likely at or near depletion. Management explicitly discloses that 'recurring losses from operations have raised substantial doubt regarding our ability to continue as a going concern,' and warns that raising capital, if achievable at all, may be 'highly dilutive to existing stockholders.' Shares already grew 15.3% YoY to 18.4M, accumulated deficit sits at -$233.7M, and stockholders' equity is a razor-thin $1.64M against $24.2M of liabilities (14.8x leverage). A dilutive raise into a $73.6M market cap is not a tail risk — it is the base case.